SCHEMBL30438257

SCHEMBL30438257

O=c1c2c(n(-c3cccc(Cl)c3)c3ncccc13)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
HPGD P15428 2/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 3/20 0.42
PDE4B Q07343 1/20 0.40
PDE4D Q08499 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
HTR6 P50406 2/20 0.39
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD1 P21728 2/20 0.37
DRD5 P21918 2/20 0.37
GAA P10253 1/20 0.37
FEN1 P39748 1/20 0.37
PDE4A P27815 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6009928 1.00 MAPT (0.49) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9132456 0.85 MAPT (0.47) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9133313 0.85 CYP2C19 (0.45) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9130617 0.84 PDE4A (0.37) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9132031 0.84 MAPT (0.44) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9535601 0.84 MAPT (0.50) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9132455 0.84 MAPT (0.48) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9134909 0.83 MAPT (0.43) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9131645 0.83 MAPT (0.43) MAPTHPGDCYP2C19MEN1CYP1A2
SCHEMBL9726870 0.83 CYP2C19 (0.47) MAPTHPGDCYP2C19MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629379-B2 Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction NIPPON CHEMIPHAR CO., LTD. (JP) 2026-05-19 US disclosed
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US disclosed
US-12233071-B2 Medicament for treating cough NIPPON CHEMIPHAR CO., LTD. (JP) 2025-02-25 US disclosed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP disclosed
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN disclosed
WO-2023190826-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS 学校法人 高崎健康福祉大学 2023-10-05 WO disclosed
US-20230277552-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION NIPPON CHEMIPHAR CO., LTD. (JP) 2023-09-07 US disclosed
US-20230248738-A1 MEDICAMENT FOR TREATING COUGH NIPPON CHEMIPHAR CO., LTD (JP) 2023-08-10 US disclosed
EP-4190356-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION Nippon Chemiphar Co., Ltd. (JP) 2023-06-07 EP disclosed
US-11666582-B2 Medicament for treating cough NIPPON CHEMIPHAR CO., LTD. (JP) 2023-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233071-B2 Medicament for treating cough P2RX4, P2RX3, P2RX5 MAPT 366/4885HPGD 1051/4885CYP2C19 2414/4885
US-11666582-B2 Medicament for treating cough P2RX4, P2RX3, P2RX5 MAPT 366/4885HPGD 1051/4885CYP2C19 2414/4885
US-12629379-B2 Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction HRH2, HRH4, HRH1 MAPT 4036/4885HPGD 1249/4885CYP2C19 889/4885
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TRPV1, TRPV4, TRPV5 MAPT 1187/4885HPGD 3579/4885CYP2C19 1168/4885
US-20230277552-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION P2RX5, P2RX3, P2RX2 MAPT 3836/4885HPGD 1532/4885CYP2C19 471/4885
US-20230248738-A1 MEDICAMENT FOR TREATING COUGH P2RX4, P2RX3, P2RX5 MAPT 366/4885HPGD 1051/4885CYP2C19 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.